Senti Biosciences Inc (SNTI) Stock Price, Quote & News

Company Profile

Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. The company's product candidates also include SENTI-202, a logic gated off-the-shelf...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 239 2030

Website: www.sentibio.com

Address:

2 Corporate Drive, First Floor, South San Francisco, United States

winners18 Oct. 2 at 4:30 PM

$SNTI best aml treatment upcoming ash data update $5 minimum

0 · Reply

kshonstocks Oct. 2 at 3:55 PM

$SNTI off the bottom scans has potential

0 · Reply

TheGhostOfEd Oct. 2 at 2:35 AM

$SNTI going to explode soon not investment advice

0 · Reply

Tradingpirate Sep. 23 at 8:36 PM

$SNTI Loading here under $1.40

0 · Reply

Raxothus Sep. 23 at 8:22 PM

EOD CONTINUATION FOLLOW-UP – 09/20/25 Tracking continuation watchlist from today based on intraday highs vs. close ❌ $SNTI – No movement. Failed continuation. ❌ $NA – No movement. Failed continuation. ❌ $SPCB – No movement. Failed continuation. ❌ $GKPRF – No movement. Failed continuation. ✅ $SSKN – Closed 1.72, HOD 3.05 (+77.3%), closed 2.65 under VWAP. Strong move but lacked close above VWAP. Recap: 5 total → 1 winner, 4 fails, 0 neutral → 20% accuracy Leader: $SSKN (+77.3% intraday) was the only continuation play, though the VWAP close limits conviction. #VWAP #SmallCaps #DayTrading #EODFollowUp #Continuation #SniperSetup #Accountability

2 · Reply

TheGhostOfEd Sep. 23 at 5:20 PM

$SNTI added another 10k

0 · Reply

Raxothus Sep. 22 at 7:43 PM

EOD CONTINUATION WATCHLIST – 09/20/25 Focused on stocks that held VWAP and pushed into Power Hour with strength $SNTI – 2.8x volume, 2.7% VWAP stretch, micro float (9.6M) 5.2% open-to-current with 0.7% late push, RSI 57.3. Watching breakout > 1.42 for continuation. $NA – 2.1x volume, 3.5% VWAP stretch, micro float (6.3M) 5.7% open-to-current with 2.4% late push, RSI 54.1. Strong candidate, watching breakout > 5.83 for continuation. $SPCB – 2.5x volume, 2.3% VWAP stretch, micro float (3.4M) 8.6% open-to-current with 0.2% late push, RSI 40.9. Watching breakout > 13.20 for continuation. $GKPRF – 1.2x volume, 0.7% VWAP stretch, medium float (89.2M) 3.6% open-to-current with 0.0% late push, RSI 46.5. Needs breakout > 1.46 for continuation. $SSKN – 13.6x volume, 7.5% VWAP stretch, micro float (1.5M) 10.3% open-to-current with 3.6% late push, RSI 62.0. Low-float leader, watching breakout > 1.73 for continuation. #EOD #VWAP #Momentum #SmallCaps #DayTrading #ContinuationSetups #PowerHourWatch

0 · Reply

Lawnchair45 Sep. 22 at 5:02 PM

$SNTI I’m smelling what Jay’s cooking.

0 · Reply

WallStDecoding Sep. 22 at 12:49 AM

BOXL is next. It’s a true unicorn setup: ✔️ Zero borrow ✔️ High short interest ✔️ $99M in real assets ✔️ $30+ intrinsic value Shorts are trapped. Chart is curled. When this goes it’ll be fast and violent…… $PHGE $YOSH $WLDS $SNTI $LEXX

0 · Reply

WallStVisions Sep. 21 at 7:22 PM

BOXL is next. You don’t get setups like this often: → No borrow → Huge short interest → Real fundamental value → Bottomed chart If this gets volume, $2 turns into $5 fast. $TRKA $REVB $BJDX $SNTI $FNGR ….

1 · Reply

Senti Bio to Present at the MedInvest Biotech & Pharma Conference

Sep 2, 2025, 9:05 AM EDT - 4 weeks ago

Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 9:15 AM EDT - 7 weeks ago

Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 12, 2025, 9:15 AM EDT - 7 weeks ago

Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia

Aug 7, 2025, 8:05 AM EDT - 2 months ago

Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025

$Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia$

Aug 5, 2025, 8:30 AM EDT - 2 months ago

Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia

Jul 22, 2025, 8:45 AM EDT - 2 months ago

Senti Biosciences Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 21, 2025, 8:55 AM EDT - 2 months ago

Senti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum

Jul 18, 2025, 8:55 AM EDT - 2 months ago

Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors

Jun 30, 2025, 9:15 AM EDT - 3 months ago

Senti Bio Participates in Nasdaq Amplify Spotlight Series

Jun 24, 2025, 8:45 AM EDT - 3 months ago

Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference

Jun 18, 2025, 7:00 AM EDT - 3 months ago

Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia

Jun 9, 2025, 4:30 PM EDT - 4 months ago

Senti Biosciences Announces New Employment Inducement Grants

Jun 6, 2025, 9:05 AM EDT - 4 months ago

Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC

May 30, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Shareholders to Inquire about Securities Investigation

May 29, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Shareholders to Connect

May 28, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Senti Biosciences, Inc. (SNTI) And Encourages Shareholders to Reach Out

May 27, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Senti Biosciences, Inc. (SNTI) and Encourages Shareholders to Learn More About the Investigation

May 26, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Senti Biosciences, Inc. (SNTI) and Encourages Investors to Learn More About the Investigation

May 25, 2025, 10:00 AM EDT - 4 months ago

Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 23, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Investors to Connect

May 22, 2025, 4:05 PM EDT - 4 months ago

Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

May 22, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Stockholders to Inquire about Securities Investigation

May 22, 2025, 8:30 AM EDT - 4 months ago

Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202

May 21, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Investors to Inquire about Securities Investigation

May 20, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Senti Biosciences, Inc. (SNTI) And Encourages Investors to Reach Out

May 20, 2025, 5:28 AM EDT - 4 months ago

SNTI Investors Have Opportunity to Join Senti Biosciences, Inc. Fraud Investigation with the Schall Law Firm

May 19, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Senti Biosciences, Inc. (SNTI) And Encourages Stockholders to Reach Out

May 18, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Stockholders to Connect

May 16, 2025, 2:00 PM EDT - 5 months ago

Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 8, 2025, 8:35 AM EDT - 5 months ago

Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202

May 6, 2025, 4:35 PM EDT - 5 months ago

Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development

May 1, 2025, 9:15 AM EDT - 5 months ago

Senti Bio Releases Virtual Investor “What This Means” Segment

Apr 30, 2025, 9:00 AM EDT - 5 months ago

Senti Bio to Present at the Citizens JMP Life Sciences Conference

$Senti Bio's SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML$

Apr 28, 2025, 7:00 AM EDT - 5 months ago

Senti Bio's SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML

Apr 24, 2025, 8:35 AM EDT - 5 months ago

Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 on Monday, April 28th at 8:30 AM ET

Apr 21, 2025, 9:05 AM EDT - 5 months ago

Senti Bio Participates in a Virtual Investor KOL Connect Segment

Apr 16, 2025, 9:15 AM EDT - 6 months ago

Senti Bio (NASDAQ: SNTI) to Participate in a Live Virtual Investor Closing Bell Segment

Apr 10, 2025, 8:45 AM EDT - 6 months ago

Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.

winners18 Oct. 2 at 4:30 PM

$SNTI best aml treatment upcoming ash data update $5 minimum

0 · Reply

kshonstocks Oct. 2 at 3:55 PM

$SNTI off the bottom scans has potential

0 · Reply

TheGhostOfEd Oct. 2 at 2:35 AM

$SNTI going to explode soon not investment advice

0 · Reply

Tradingpirate Sep. 23 at 8:36 PM

$SNTI Loading here under $1.40

0 · Reply

Raxothus Sep. 23 at 8:22 PM

2 · Reply

TheGhostOfEd Sep. 23 at 5:20 PM

$SNTI added another 10k

0 · Reply

Raxothus Sep. 22 at 7:43 PM

0 · Reply

Lawnchair45 Sep. 22 at 5:02 PM

$SNTI I’m smelling what Jay’s cooking.

0 · Reply

WallStDecoding Sep. 22 at 12:49 AM

0 · Reply

WallStVisions Sep. 21 at 7:22 PM

1 · Reply

WallStDecoding Sep. 20 at 2:53 AM

BOXL is next. I’ve nailed plays before they’ve exploded and this chart is one of the cleanest. Golden cross forming. Bottomed and loaded. If this curls above key levels, it could gap hard. Perfect swing trigger. $MBOT $TRKA $STSS $SNTI $NAOV

0 · Reply

WallStDecoding Sep. 20 at 2:11 AM

BOXL the 10 bagger written in stone. “Zero borrow” is a big deal. Means shorts can’t easily borrow to bet down the ticker. Add intrinsic value north of $100 in some models, strong asset base, and strong utilization metrics and BOXL has the setup for a rocket once people notice. $CRKN $YOSH $NAOV $SNTI $COSM

0 · Reply

Devoted2Execution Sep. 19 at 2:12 AM

VRME is sitting on a breakout setup: ✅ Cash flow positive ✅ Golden cross forming ✅ Low float ✅ Recent UPS logistics deal This is the exact kind of quiet chart that gaps 100%+ once volume shows up. $TMBR $REVB $CRKN $SNTI

0 · Reply

TheGhostOfEd Sep. 18 at 3:10 AM

$SNTI Soon.....offering also coming

0 · Reply

WallStVisions Sep. 17 at 11:39 AM

EDUC is the perfect storm: – Profitable – No debt pressure – $32M in fresh liquidity – Float is light With the chart bottomed and news in the rearview, the next leg could be massive. $NAOV $SNTI $PHUN $WLDS $MBOT ..

0 · Reply

ExecutiveEdge Sep. 16 at 5:31 PM

MSN Cash-rich. No dilution. Golden cross curling. $MSN is the kind of setup traders dream about before it hits the scanner. This could be one of those “remember when it was 90 cents” trades. $PHUN $SNTI $VCNX $WLDS $AGBA

1 · Reply

Moneymastermind99 Sep. 16 at 1:26 PM

🔥 Don’t sleep on what’s happening in the markets — look at recent monster runners: $NVOS, $MGRX, $SNTI, and $VGAS all made massive moves from pennies to multi-dollar levels. 🚀 The right setup + real catalysts = life-changing gains. $TGL has all the ingredients — low float, strategic expansion, upcoming AI/crypto plays, and growing visibility. Volatility is expected, but that’s where opportunity lives. Hold strong, don’t let cheap hands shake you out. Big runs start just like this. 💎🙌

1 · Reply

Pipelinepivots Sep. 14 at 3:59 AM

MITQ looks identical to MCVT before it ripped. Micro float. Chart base is tight. Golden cross is loading. This is one of the few small caps left with serious multi-bagger potential. Eyes will come late. Be early. $SHPH $CRXT $AVTX $SNTI $QNRX

0 · Reply

TheGhostOfEd Sep. 11 at 6:43 PM

$SNTI Looking for a run soon

0 · Reply

AbhiSg Sep. 11 at 12:09 PM

$SNTI how much is the possibility you see, that this stock have chances to delist?

1 · Reply

PSM_EmpowerTrading Sep. 10 at 2:29 PM

⌛️⏳️ Potential swing ideas 💡 ✅️ $XTKG recently announced partnership with T5 Data Centers to boost AI Development in Pennsylvania, Clear Street price target $6, Northland Securities price target $3.25, HC Wainwright price target $3.50, Alliance Global Partners buy rating price target $3.25, company specializes in mining $BTC using its own infrastructure including data centers and energy assets ✅️ $SNTI recently received FDA orphan drug designation for treatment of acute myeloid leukemia, recently received additional $1M from CIRM (California Institute for Regenerative Medicines) to support clinical development, Chardan Capital price target $12, Laidlaw & Co price price $15, company focuses on the development of next-generation cell and gene therapies through tis proprietary Gene Circuit platform, lead candidate, SENT-202, upcoming catalyst: 1) data for phase 1 SENT-202 study in acute myeloid leukemia expected Q4, 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D

0 · Reply

NVDAMillionaire Sep. 10 at 8:05 AM

$SNTI Really good write-up that perfectly summarizes SNTI's present situation. So if you want to bring your SNTI knowledge up to date or just discover SNTI, this is required reading. https://beyondspx.com/quote/SNTI/analysis/senti-biosciences-the-logic-gate-to-next-gen-cell-therapies-faces-critical-inflection-nasdaq-snti

1 · Reply

Market Cap	41.86M
Revenue (ttm)	0.00
Net Income (ttm)	-52.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	349,600
Avg Vol	130,132
Day's Range	N/A - N/A
Shares Out	26.16M
Stochastic %K	69%
Beta	2.04
Analysts	Sell
Price Target	$12.00